English

Pharma-Bio Serv, Inc.

EDGAR

PBSV Quarterly report (10-Q) · filed 2026-09-14

Annual consolidated revenue for 2025: about USD 9.001M, using the latest reported figures. The previous period, 2024, was about USD 9.509M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

2.34 million USD

2026 Q3 · USD

Exact inputs and evidence

Revenue: 2336055 USD Source

Operating margin

-3.07%

2026 Q3 · %

Exact inputs and evidence

Operating Income: -71812 USD Source
Revenue: 2336055 USD Source

Operating cash flow

60.9 thousand USD

2026 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: 60892 USD Source

Free cash flow

59.5 thousand USD

2026 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: 60892 USD Source
Capital Expenditure: 1390 USD Source

Cash and cash equivalents: 2.87 million USD 2023-07-31 Source
Exact value

2869584 USD
Long-term debt including current maturities: Not available
Shares outstanding: 22.9 million shares 2026-07-31 Source
Exact value

22901692 shares

Reported share-count change

-0.08% · -18.8 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

22920442 shares · 2025-07-31· Source
22901692 shares · 2026-07-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

9.48 million USD

2025-08-01 – 2026-07-31

Exact inputs and evidence

Revenue: 9001096 USD · 2024-11-01 – 2025-10-31 Source
Revenue: 6851460 USD · 2024-11-01 – 2025-07-31 Source
Revenue: 2294966 USD · 2025-11-01 – 2026-01-31 Source
Revenue: 2702943 USD · 2026-02-01 – 2026-04-30 Source
Revenue: 2336055 USD · 2026-05-01 – 2026-07-31 Source

Net income

252 thousand USD

2025-08-01 – 2026-07-31

Exact inputs and evidence

Net income: -100463 USD · 2024-11-01 – 2025-10-31 Source
Net income: -100361 USD · 2024-11-01 – 2025-07-31 Source
Net income: 32860 USD · 2025-11-01 – 2026-01-31 Source
Net income: 232986 USD · 2026-02-01 – 2026-04-30 Source
Net income: -14219 USD · 2026-05-01 – 2026-07-31 Source

Operating cash flow

-415 thousand USD

2025-08-01 – 2026-07-31

Exact inputs and evidence

Operating cash flow: -214886 USD · 2024-11-01 – 2025-10-31 Source
Operating cash flow: -494552 USD · 2024-11-01 – 2025-07-31 Source
Operating cash flow: -390139 USD · 2025-11-01 – 2026-01-31 Source
Operating cash flow: -365311 USD · 2026-02-01 – 2026-04-30 Source
Operating cash flow: 60892 USD · 2026-05-01 – 2026-07-31 Source

Capital expenditure

6.47 thousand USD

2025-08-01 – 2026-07-31

Exact inputs and evidence

Capital expenditure: 6644 USD · 2024-11-01 – 2025-10-31 Source
Capital expenditure: 6294 USD · 2024-11-01 – 2025-07-31 Source
Capital expenditure: 2411 USD · 2025-11-01 – 2026-01-31 Source
Capital expenditure: 2321 USD · 2026-02-01 – 2026-04-30 Source
Capital expenditure: 1390 USD · 2026-05-01 – 2026-07-31 Source

Free cash flow

-421 thousand USD

2025-08-01 – 2026-07-31

Exact inputs and evidence

Operating cash flow: -214886 USD · 2024-11-01 – 2025-10-31 Source
Operating cash flow: -494552 USD · 2024-11-01 – 2025-07-31 Source
Operating cash flow: -390139 USD · 2025-11-01 – 2026-01-31 Source
Operating cash flow: -365311 USD · 2026-02-01 – 2026-04-30 Source
Operating cash flow: 60892 USD · 2026-05-01 – 2026-07-31 Source
Capital expenditure: 6644 USD · 2024-11-01 – 2025-10-31 Source
Capital expenditure: 6294 USD · 2024-11-01 – 2025-07-31 Source
Capital expenditure: 2411 USD · 2025-11-01 – 2026-01-31 Source
Capital expenditure: 2321 USD · 2026-02-01 – 2026-04-30 Source
Capital expenditure: 1390 USD · 2026-05-01 – 2026-07-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-09-14.

Financial data available through: 2025-10-31.

Coverage by financial measure

Revenue: 9 of 11 periods available· newest 2025-10-31
Operating income: 11 of 11 periods available· newest 2025-10-31
Net income: 11 of 11 periods available· newest 2025-10-31
Operating cash flow: 11 of 11 periods available· newest 2025-10-31
Capital expenditure: 11 of 11 periods available· newest 2025-10-31
Total assets: 9 of 11 periods available· newest 2025-10-31
Total liabilities: 9 of 11 periods available· newest 2025-10-31
Current assets: 9 of 11 periods available· newest 2025-10-31
Current liabilities: 9 of 11 periods available· newest 2025-10-31
Cash and cash equivalents: 6 of 11 periods available· newest 2022-10-31
long term debt: No compatible figures in this window
Shares outstanding: 9 of 11 periods available· newest 2025-10-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-5.3%

Prior period

USD 9.51 million

2023-11-01 – 2024-10-31
Current period

USD 9 million

2024-11-01 – 2025-10-31

Exact inputs and evidence

9001096 − 9509279 = -508183 USD

9509279 USD · 2023-11-01 – 2024-10-31
Inspect prior input Prior source
9001096 USD · 2024-11-01 – 2025-10-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Pharma-Bio Serv, Inc. · 2025-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Year-over-year change in Revenue: -508183 USD Concept: fundies:Revenue Period: 2024-11-01 to 2025-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 9001096 USD (2024-11-01 to 2025-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495426000710/pbsv_10k.htm#925157 Filing: 000165495426000710 Input fundies:Revenue: 9509279 USD (2023-11-01 to 2024-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495426000710/pbsv_10k.htm#925942 Filing: 000165495426000710
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 677,156

Prior period

−USD 777,619

2023-11-01 – 2024-10-31
Current period

−USD 100,463

2024-11-01 – 2025-10-31

Exact inputs and evidence

-100463 − -777619 = 677156 USD

-777619 USD · 2023-11-01 – 2024-10-31
Inspect prior input Prior source
-100463 USD · 2024-11-01 – 2025-10-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Pharma-Bio Serv, Inc. · 2025-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Year-over-year change in Net income: 677156 USD Concept: fundies:NetIncome Period: 2024-11-01 to 2025-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -100463 USD (2024-11-01 to 2025-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495426000710/pbsv_10k.htm#837901 Filing: 000165495426000710 Input fundies:NetIncome: -777619 USD (2023-11-01 to 2024-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495426000710/pbsv_10k.htm#838503 Filing: 000165495426000710
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 351,815

Prior period

−USD 566,701

2023-11-01 – 2024-10-31
Current period

−USD 214,886

2024-11-01 – 2025-10-31

Exact inputs and evidence

-214886 − -566701 = 351815 USD

-566701 USD · 2023-11-01 – 2024-10-31
Inspect prior input Prior source
-214886 USD · 2024-11-01 – 2025-10-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Pharma-Bio Serv, Inc. · 2025-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Year-over-year change in Operating cash flow: 351815 USD Concept: fundies:OperatingCashFlow Period: 2024-11-01 to 2025-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -214886 USD (2024-11-01 to 2025-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495426000710/pbsv_10k.htm#723122 Filing: 000165495426000710 Input fundies:OperatingCashFlow: -566701 USD (2023-11-01 to 2024-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495426000710/pbsv_10k.htm#723804 Filing: 000165495426000710
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-95.8%

Prior period

USD 159,743

2023-11-01 – 2024-10-31
Current period

USD 6,644

2024-11-01 – 2025-10-31

Exact inputs and evidence

6644 − 159743 = -153099 USD

159743 USD · 2023-11-01 – 2024-10-31
Inspect prior input Prior source
6644 USD · 2024-11-01 – 2025-10-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Pharma-Bio Serv, Inc. · 2025-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Year-over-year change in Capital expenditure: -153099 USD Concept: fundies:CapitalExpenditure Period: 2024-11-01 to 2025-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 6644 USD (2024-11-01 to 2025-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495426000710/pbsv_10k.htm#726926 Filing: 000165495426000710 Input fundies:CapitalExpenditure: 159743 USD (2023-11-01 to 2024-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495426000710/pbsv_10k.htm#727527 Filing: 000165495426000710
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2024-11-01 – 2025-10-31

Revenue USD 9 million 100% of revenue
Operating costs Derived USD 9.64 million 107% of revenue
Operating income −USD 637,662 −7.1% of revenue
Tax, interest and other Derived −USD 537,199 −6% of revenue
Net income −USD 100,463 −1.1% of revenue

Cash

Operating cash flow −USD 214,886 −2.4% of revenue
Capital expenditure USD 6,644 0.1% of revenue
Free cash flow Derived −USD 221,530 −2.5% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2017 Operating loss: operating costs were 106% of revenue.
2018 Operating loss: operating costs were 107% of revenue.
2019 Net income was higher than operating income, so the split is not drawn.
2020 9.5%90%
2021 Operating loss: operating costs were 119% of revenue.
2022 94%
2023 Net income was higher than operating income, so the split is not drawn.
2024 Operating loss: operating costs were 114% of revenue.
2025 Operating loss: operating costs were 107% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2017 2016-11-01 – 2017-10-31	13297598	14075416 Derived	-777818	637091 Derived	-1414909	-979640 Derived	Source 2016-11-01 – 2017-10-31: 13297598 USD Inspect Revenue Open source 2016-11-01 – 2017-10-31: -777818 USD Inspect Operating Income Open source 2016-11-01 – 2017-10-31: -1414909 USD Inspect Net Income Open source 2016-11-01 – 2017-10-31: -922667 USD Inspect Operating Cash Flow Open source 2016-11-01 – 2017-10-31: 56973 USD Inspect Capital Expenditure Open source
2018 2017-11-01 – 2018-10-31	17797425	19059161 Derived	-1261736	-2541470 Derived	1279734	3596675 Derived	Source 2017-11-01 – 2018-10-31: 17797425 USD Inspect Revenue Open source 2017-11-01 – 2018-10-31: -1261736 USD Inspect Operating Income Open source 2017-11-01 – 2018-10-31: 1279734 USD Inspect Net Income Open source 2017-11-01 – 2018-10-31: 3718684 USD Inspect Operating Cash Flow Open source 2017-11-01 – 2018-10-31: 122009 USD Inspect Capital Expenditure Open source
2019 2018-11-01 – 2019-10-31	19506911	17810228 Derived	1696683	-390573 Derived	2087256	-2265118 Derived	Source 2018-11-01 – 2019-10-31: 19506911 USD Inspect Revenue Open source 2018-11-01 – 2019-10-31: 1696683 USD Inspect Operating Income Open source 2018-11-01 – 2019-10-31: 2087256 USD Inspect Net Income Open source 2018-11-01 – 2019-10-31: -2207739 USD Inspect Operating Cash Flow Open source 2018-11-01 – 2019-10-31: 57379 USD Inspect Capital Expenditure Open source
2020 2019-11-01 – 2020-10-31	21564360	19338813 Derived	2225547	174625 Derived	2050922	1458755 Derived	Source 2019-11-01 – 2020-10-31: 21564360 USD Inspect Revenue Open source 2019-11-01 – 2020-10-31: 2225547 USD Inspect Operating Income Open source 2019-11-01 – 2020-10-31: 2050922 USD Inspect Net Income Open source 2019-11-01 – 2020-10-31: 1514412 USD Inspect Operating Cash Flow Open source 2019-11-01 – 2020-10-31: 55657 USD Inspect Capital Expenditure Open source
2021 2020-11-01 – 2021-10-31	20115175	23968869 Derived	-3853694	-1764454 Derived	-2089240	793997 Derived	Source 2020-11-01 – 2021-10-31: 20115175 USD Inspect Revenue Open source 2020-11-01 – 2021-10-31: -3853694 USD Inspect Operating Income Open source 2020-11-01 – 2021-10-31: -2089240 USD Inspect Net Income Open source 2020-11-01 – 2021-10-31: 804842 USD Inspect Operating Cash Flow Open source 2020-11-01 – 2021-10-31: 10845 USD Inspect Capital Expenditure Open source
2022 2021-11-01 – 2022-10-31	19398727	18223782 Derived	1174945	168261 Derived	1006684	573188 Derived	Source 2021-11-01 – 2022-10-31: 19398727 USD Inspect Revenue Open source 2021-11-01 – 2022-10-31: 1174945 USD Inspect Operating Income Open source 2021-11-01 – 2022-10-31: 1006684 USD Inspect Net Income Open source 2021-11-01 – 2022-10-31: 592457 USD Inspect Operating Cash Flow Open source 2021-11-01 – 2022-10-31: 19269 USD Inspect Capital Expenditure Open source
2023 2022-11-01 – 2023-10-31	16976856	15859445 Derived	1117411	-192769 Derived	1310180	1883709 Derived	Source 2022-11-01 – 2023-10-31: 16976856 USD Inspect Revenue Open source 2022-11-01 – 2023-10-31: 1117411 USD Inspect Operating Income Open source 2022-11-01 – 2023-10-31: 1310180 USD Inspect Net Income Open source 2022-11-01 – 2023-10-31: 1890960 USD Inspect Operating Cash Flow Open source 2022-11-01 – 2023-10-31: 7251 USD Inspect Capital Expenditure Open source
2024 2023-11-01 – 2024-10-31	9509279	10796866 Derived	-1287587	-509968 Derived	-777619	-726444 Derived	Source 2023-11-01 – 2024-10-31: 9509279 USD Inspect Revenue Open source 2023-11-01 – 2024-10-31: -1287587 USD Inspect Operating Income Open source 2023-11-01 – 2024-10-31: -777619 USD Inspect Net Income Open source 2023-11-01 – 2024-10-31: -566701 USD Inspect Operating Cash Flow Open source 2023-11-01 – 2024-10-31: 159743 USD Inspect Capital Expenditure Open source
2025 2024-11-01 – 2025-10-31	9001096	9638758 Derived	-637662	-537199 Derived	-100463	-221530 Derived	Source 2024-11-01 – 2025-10-31: 9001096 USD Inspect Revenue Open source 2024-11-01 – 2025-10-31: -637662 USD Inspect Operating Income Open source 2024-11-01 – 2025-10-31: -100463 USD Inspect Net Income Open source 2024-11-01 – 2025-10-31: -214886 USD Inspect Operating Cash Flow Open source 2024-11-01 – 2025-10-31: 6644 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 9M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-10-31	Revenue	13297598	Revenue: 13297598 Open source
20182018-10-31	Revenue	17797425	Revenue: 17797425 Open source
20192019-10-31	Revenue	19506911	Revenue: 19506911 Open source
20202020-10-31	Revenue	21564360	Revenue: 21564360 Open source
20212021-10-31	Revenue	20115175	Revenue: 20115175 Open source
20222022-10-31	Revenue	19398727	Revenue: 19398727 Open source
20232023-10-31	Revenue	16976856	Revenue: 16976856 Open source
20242024-10-31	Revenue	9509279	Revenue: 9509279 Open source
20252025-10-31	Revenue	9001096	Revenue: 9001096 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-5.3% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20172017-10-31	Year over year	No prior comparable period	Revenue: 13297598 Open source
20182018-10-31	Year over year	33.8%	Revenue: 17797425 Open source Revenue: 13297598 Open source
20192019-10-31	Year over year	9.6%	Revenue: 19506911 Open source Revenue: 17797425 Open source
20202020-10-31	Year over year	10.5%	Revenue: 21564360 Open source Revenue: 19506911 Open source
20212021-10-31	Year over year	-6.7%	Revenue: 20115175 Open source Revenue: 21564360 Open source
20222022-10-31	Year over year	-3.6%	Revenue: 19398727 Open source Revenue: 20115175 Open source
20232023-10-31	Year over year	-12.5%	Revenue: 16976856 Open source Revenue: 19398727 Open source
20242024-10-31	Year over year	-44%	Revenue: 9509279 Open source Revenue: 16976856 Open source
20252025-10-31	Year over year	-5.3%	Revenue: 9001096 Open source Revenue: 9509279 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -7.1% 2025

Net margin -1.1% 2025

Free cash flow margin -2.5% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20172017-10-31	Operating margin	-5.8%	Operating Income: -777818 Open source Revenue: 13297598 Open source
20182018-10-31	Operating margin	-7.1%	Operating Income: -1261736 Open source Revenue: 17797425 Open source
20192019-10-31	Operating margin	8.7%	Operating Income: 1696683 Open source Revenue: 19506911 Open source
20202020-10-31	Operating margin	10.3%	Operating Income: 2225547 Open source Revenue: 21564360 Open source
20212021-10-31	Operating margin	-19.2%	Operating Income: -3853694 Open source Revenue: 20115175 Open source
20222022-10-31	Operating margin	6.1%	Operating Income: 1174945 Open source Revenue: 19398727 Open source
20232023-10-31	Operating margin	6.6%	Operating Income: 1117411 Open source Revenue: 16976856 Open source
20242024-10-31	Operating margin	-13.5%	Operating Income: -1287587 Open source Revenue: 9509279 Open source
20252025-10-31	Operating margin	-7.1%	Operating Income: -637662 Open source Revenue: 9001096 Open source
20172017-10-31	Net margin	-10.6%	Net Income: -1414909 Open source Revenue: 13297598 Open source
20182018-10-31	Net margin	7.2%	Net Income: 1279734 Open source Revenue: 17797425 Open source
20192019-10-31	Net margin	10.7%	Net Income: 2087256 Open source Revenue: 19506911 Open source
20202020-10-31	Net margin	9.5%	Net Income: 2050922 Open source Revenue: 21564360 Open source
20212021-10-31	Net margin	-10.4%	Net Income: -2089240 Open source Revenue: 20115175 Open source
20222022-10-31	Net margin	5.2%	Net Income: 1006684 Open source Revenue: 19398727 Open source
20232023-10-31	Net margin	7.7%	Net Income: 1310180 Open source Revenue: 16976856 Open source
20242024-10-31	Net margin	-8.2%	Net Income: -777619 Open source Revenue: 9509279 Open source
20252025-10-31	Net margin	-1.1%	Net Income: -100463 Open source Revenue: 9001096 Open source
20172017-10-31	Free cash flow margin	-7.4%	Revenue: 13297598 Open source Operating Cash Flow: -922667 Open source Capital Expenditure: 56973 Open source
20182018-10-31	Free cash flow margin	20.2%	Revenue: 17797425 Open source Operating Cash Flow: 3718684 Open source Capital Expenditure: 122009 Open source
20192019-10-31	Free cash flow margin	-11.6%	Revenue: 19506911 Open source Operating Cash Flow: -2207739 Open source Capital Expenditure: 57379 Open source
20202020-10-31	Free cash flow margin	6.8%	Revenue: 21564360 Open source Operating Cash Flow: 1514412 Open source Capital Expenditure: 55657 Open source
20212021-10-31	Free cash flow margin	3.9%	Revenue: 20115175 Open source Operating Cash Flow: 804842 Open source Capital Expenditure: 10845 Open source
20222022-10-31	Free cash flow margin	3%	Revenue: 19398727 Open source Operating Cash Flow: 592457 Open source Capital Expenditure: 19269 Open source
20232023-10-31	Free cash flow margin	11.1%	Revenue: 16976856 Open source Operating Cash Flow: 1890960 Open source Capital Expenditure: 7251 Open source
20242024-10-31	Free cash flow margin	-7.6%	Revenue: 9509279 Open source Operating Cash Flow: -566701 Open source Capital Expenditure: 159743 Open source
20252025-10-31	Free cash flow margin	-2.5%	Revenue: 9001096 Open source Operating Cash Flow: -214886 Open source Capital Expenditure: 6644 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -214.9K 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-10-31	Operating cash flow	-922667	Operating Cash Flow: -922667 Open source
20182018-10-31	Operating cash flow	3718684	Operating Cash Flow: 3718684 Open source
20192019-10-31	Operating cash flow	-2207739	Operating Cash Flow: -2207739 Open source
20202020-10-31	Operating cash flow	1514412	Operating Cash Flow: 1514412 Open source
20212021-10-31	Operating cash flow	804842	Operating Cash Flow: 804842 Open source
20222022-10-31	Operating cash flow	592457	Operating Cash Flow: 592457 Open source
20232023-10-31	Operating cash flow	1890960	Operating Cash Flow: 1890960 Open source
20242024-10-31	Operating cash flow	-566701	Operating Cash Flow: -566701 Open source
20252025-10-31	Operating cash flow	-214886	Operating Cash Flow: -214886 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -221.5K 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-10-31	Free cash flow	-979640	Operating Cash Flow: -922667 Open source Capital Expenditure: 56973 Open source
20182018-10-31	Free cash flow	3596675	Operating Cash Flow: 3718684 Open source Capital Expenditure: 122009 Open source
20192019-10-31	Free cash flow	-2265118	Operating Cash Flow: -2207739 Open source Capital Expenditure: 57379 Open source
20202020-10-31	Free cash flow	1458755	Operating Cash Flow: 1514412 Open source Capital Expenditure: 55657 Open source
20212021-10-31	Free cash flow	793997	Operating Cash Flow: 804842 Open source Capital Expenditure: 10845 Open source
20222022-10-31	Free cash flow	573188	Operating Cash Flow: 592457 Open source Capital Expenditure: 19269 Open source
20232023-10-31	Free cash flow	1883709	Operating Cash Flow: 1890960 Open source Capital Expenditure: 7251 Open source
20242024-10-31	Free cash flow	-726444	Operating Cash Flow: -566701 Open source Capital Expenditure: 159743 Open source
20252025-10-31	Free cash flow	-221530	Operating Cash Flow: -214886 Open source Capital Expenditure: 6644 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

12.7% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20172017-10-31	Liabilities / assets	7.2%	Total Liabilities: 1602715 Open source Total Assets: 22350001 Open source
20182018-10-31	Liabilities / assets	20.2%	Total Liabilities: 5114649 Open source Total Assets: 25378312 Open source
20192019-10-31	Liabilities / assets	22.6%	Total Liabilities: 6025569 Open source Total Assets: 26633075 Open source
20202020-10-31	Liabilities / assets	24.1%	Total Liabilities: 7202085 Open source Total Assets: 29918746 Open source
20212021-10-31	Liabilities / assets	20.9%	Total Liabilities: 5007070 Open source Total Assets: 23921201 Open source
20222022-10-31	Liabilities / assets	19.8%	Total Liabilities: 4093276 Open source Total Assets: 20650846 Open source
20232023-10-31	Liabilities / assets	19%	Total Liabilities: 3775276 Open source Total Assets: 19902061 Open source
20242024-10-31	Liabilities / assets	15.8%	Total Liabilities: 2576903 Open source Total Assets: 16292230 Open source
20252025-10-31	Liabilities / assets	12.7%	Total Liabilities: 1738799 Open source Total Assets: 13653046 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

7.7× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20172017-10-31	Current assets / current liabilities	14.05×	Current Assets: 21676464 Open source Current Liabilities: 1542920 Open source
20182018-10-31	Current assets / current liabilities	9.13×	Current Assets: 23411797 Open source Current Liabilities: 2565672 Open source
20192019-10-31	Current assets / current liabilities	7.08×	Current Assets: 25974980 Open source Current Liabilities: 3670540 Open source
20202020-10-31	Current assets / current liabilities	7.54×	Current Assets: 28584218 Open source Current Liabilities: 3792793 Open source
20212021-10-31	Current assets / current liabilities	8.55×	Current Assets: 22822356 Open source Current Liabilities: 2669170 Open source
20222022-10-31	Current assets / current liabilities	9.46×	Current Assets: 19943603 Open source Current Liabilities: 2107719 Open source
20232023-10-31	Current assets / current liabilities	9.01×	Current Assets: 19401097 Open source Current Liabilities: 2153681 Open source
20242024-10-31	Current assets / current liabilities	8.32×	Current Assets: 15698753 Open source Current Liabilities: 1887166 Open source
20252025-10-31	Current assets / current liabilities	7.7×	Current Assets: 13386845 Open source Current Liabilities: 1738799 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2015-11-01 – 2016-10-31	−USD 256,575 Exact value Exact value: -256575 USD 2015-11-01 – 2016-10-31: -256575 USD Inspect Net Income Open source Share or cite Citation for Net Income · Pharma-Bio Serv, Inc. · 2016-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Net Income: -256575 USD Concept: fundies:NetIncome Period: 2015-11-01 to 2016-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3ANetIncome&period=2016-10-31&surface=latest&period_type=duration&start=2015-11-01&unit=USD&dimensions= Input fundies:NetIncome: -256575 USD (2015-11-01 to 2016-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495418000819/pbsv-20171031.xml#77365 Filing: 000165495418000819 The citation records this snapshot. The page link may show a newer release later.	USD 709,653 Exact value Exact value: 709653 USD 2015-11-01 – 2016-10-31: 709653 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pharma-Bio Serv, Inc. · 2016-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Operating Cash Flow: 709653 USD Concept: fundies:OperatingCashFlow Period: 2015-11-01 to 2016-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3AOperatingCashFlow&period=2016-10-31&surface=latest&period_type=duration&start=2015-11-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 709653 USD (2015-11-01 to 2016-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495418000819/pbsv-20171031.xml#89617 Filing: 000165495418000819 The citation records this snapshot. The page link may show a newer release later.	USD 1.81 million Exact value Exact value: 1808632 USD 2015-11-01 – 2016-10-31: 1808632 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pharma-Bio Serv, Inc. · 2016-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Capital Expenditure: 1808632 USD Concept: fundies:CapitalExpenditure Period: 2015-11-01 to 2016-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3ACapitalExpenditure&period=2016-10-31&surface=latest&period_type=duration&start=2015-11-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1808632 USD (2015-11-01 to 2016-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495418000819/pbsv-20171031.xml#89983 Filing: 000165495418000819 The citation records this snapshot. The page link may show a newer release later.	−USD 1.1 million Calculation and evidence 709653 − 1808632 USD Exact free cash flow: -1098979 USD 2015-11-01 – 2016-10-31: 709653 USD · Inspect Operating Cash Flow · Source 2015-11-01 – 2016-10-31: 1808632 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pharma-Bio Serv, Inc. · 2016-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Free cash flow: -1098979 USD Concept: free-cash-flow Period: 2015-11-01 to 2016-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 709653 USD (2015-11-01 to 2016-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495418000819/pbsv-20171031.xml#89617 Filing: 000165495418000819 Input fundies:CapitalExpenditure: 1808632 USD (2015-11-01 to 2016-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495418000819/pbsv-20171031.xml#89983 Filing: 000165495418000819 The citation records this snapshot. The page link may show a newer release later.
2017 2016-11-01 – 2017-10-31	−USD 1.41 million Exact value Exact value: -1414909 USD 2016-11-01 – 2017-10-31: -1414909 USD Inspect Net Income Open source Share or cite Citation for Net Income · Pharma-Bio Serv, Inc. · 2017-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Net Income: -1414909 USD Concept: fundies:NetIncome Period: 2016-11-01 to 2017-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3ANetIncome&period=2017-10-31&surface=latest&period_type=duration&start=2016-11-01&unit=USD&dimensions= Input fundies:NetIncome: -1414909 USD (2016-11-01 to 2017-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495419000854/pbsv-20181031.xml#74470 Filing: 000165495419000854 The citation records this snapshot. The page link may show a newer release later.	−USD 922,667 Exact value Exact value: -922667 USD 2016-11-01 – 2017-10-31: -922667 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pharma-Bio Serv, Inc. · 2017-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Operating Cash Flow: -922667 USD Concept: fundies:OperatingCashFlow Period: 2016-11-01 to 2017-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3AOperatingCashFlow&period=2017-10-31&surface=latest&period_type=duration&start=2016-11-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -922667 USD (2016-11-01 to 2017-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495419000854/pbsv-20181031.xml#85321 Filing: 000165495419000854 The citation records this snapshot. The page link may show a newer release later.	USD 56,973 Exact value Exact value: 56973 USD 2016-11-01 – 2017-10-31: 56973 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pharma-Bio Serv, Inc. · 2017-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Capital Expenditure: 56973 USD Concept: fundies:CapitalExpenditure Period: 2016-11-01 to 2017-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3ACapitalExpenditure&period=2017-10-31&surface=latest&period_type=duration&start=2016-11-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 56973 USD (2016-11-01 to 2017-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495419000854/pbsv-20181031.xml#85688 Filing: 000165495419000854 The citation records this snapshot. The page link may show a newer release later.	−USD 979,640 Calculation and evidence -922667 − 56973 USD Exact free cash flow: -979640 USD 2016-11-01 – 2017-10-31: -922667 USD · Inspect Operating Cash Flow · Source 2016-11-01 – 2017-10-31: 56973 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pharma-Bio Serv, Inc. · 2017-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Free cash flow: -979640 USD Concept: free-cash-flow Period: 2016-11-01 to 2017-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -922667 USD (2016-11-01 to 2017-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495419000854/pbsv-20181031.xml#85321 Filing: 000165495419000854 Input fundies:CapitalExpenditure: 56973 USD (2016-11-01 to 2017-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495419000854/pbsv-20181031.xml#85688 Filing: 000165495419000854 The citation records this snapshot. The page link may show a newer release later.
2018 2017-11-01 – 2018-10-31	USD 1.28 million Exact value Exact value: 1279734 USD 2017-11-01 – 2018-10-31: 1279734 USD Inspect Net Income Open source Share or cite Citation for Net Income · Pharma-Bio Serv, Inc. · 2018-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Net Income: 1279734 USD Concept: fundies:NetIncome Period: 2017-11-01 to 2018-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3ANetIncome&period=2018-10-31&surface=latest&period_type=duration&start=2017-11-01&unit=USD&dimensions= Input fundies:NetIncome: 1279734 USD (2017-11-01 to 2018-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495420000889/pbsv-20181031.xml#76035 Filing: 000165495420000889 The citation records this snapshot. The page link may show a newer release later.	USD 3.72 million Exact value Exact value: 3718684 USD 2017-11-01 – 2018-10-31: 3718684 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pharma-Bio Serv, Inc. · 2018-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Operating Cash Flow: 3718684 USD Concept: fundies:OperatingCashFlow Period: 2017-11-01 to 2018-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3AOperatingCashFlow&period=2018-10-31&surface=latest&period_type=duration&start=2017-11-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 3718684 USD (2017-11-01 to 2018-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495420000889/pbsv-20181031.xml#86993 Filing: 000165495420000889 The citation records this snapshot. The page link may show a newer release later.	USD 122,009 Exact value Exact value: 122009 USD 2017-11-01 – 2018-10-31: 122009 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pharma-Bio Serv, Inc. · 2018-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Capital Expenditure: 122009 USD Concept: fundies:CapitalExpenditure Period: 2017-11-01 to 2018-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3ACapitalExpenditure&period=2018-10-31&surface=latest&period_type=duration&start=2017-11-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 122009 USD (2017-11-01 to 2018-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495420000889/pbsv-20181031.xml#87359 Filing: 000165495420000889 The citation records this snapshot. The page link may show a newer release later.	USD 3.6 million Calculation and evidence 3718684 − 122009 USD Exact free cash flow: 3596675 USD 2017-11-01 – 2018-10-31: 3718684 USD · Inspect Operating Cash Flow · Source 2017-11-01 – 2018-10-31: 122009 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pharma-Bio Serv, Inc. · 2018-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Free cash flow: 3596675 USD Concept: free-cash-flow Period: 2017-11-01 to 2018-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 3718684 USD (2017-11-01 to 2018-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495420000889/pbsv-20181031.xml#86993 Filing: 000165495420000889 Input fundies:CapitalExpenditure: 122009 USD (2017-11-01 to 2018-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495420000889/pbsv-20181031.xml#87359 Filing: 000165495420000889 The citation records this snapshot. The page link may show a newer release later.
2019 2018-11-01 – 2019-10-31	USD 2.09 million Exact value Exact value: 2087256 USD 2018-11-01 – 2019-10-31: 2087256 USD Inspect Net Income Open source Share or cite Citation for Net Income · Pharma-Bio Serv, Inc. · 2019-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Net Income: 2087256 USD Concept: fundies:NetIncome Period: 2018-11-01 to 2019-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3ANetIncome&period=2019-10-31&surface=latest&period_type=duration&start=2018-11-01&unit=USD&dimensions= Input fundies:NetIncome: 2087256 USD (2018-11-01 to 2019-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495421000973/pbsv-20201031.xml#74660 Filing: 000165495421000973 The citation records this snapshot. The page link may show a newer release later.	−USD 2.21 million Exact value Exact value: -2207739 USD 2018-11-01 – 2019-10-31: -2207739 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pharma-Bio Serv, Inc. · 2019-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Operating Cash Flow: -2207739 USD Concept: fundies:OperatingCashFlow Period: 2018-11-01 to 2019-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3AOperatingCashFlow&period=2019-10-31&surface=latest&period_type=duration&start=2018-11-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -2207739 USD (2018-11-01 to 2019-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495421000973/pbsv-20201031.xml#87296 Filing: 000165495421000973 The citation records this snapshot. The page link may show a newer release later.	USD 57,379 Exact value Exact value: 57379 USD 2018-11-01 – 2019-10-31: 57379 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pharma-Bio Serv, Inc. · 2019-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Capital Expenditure: 57379 USD Concept: fundies:CapitalExpenditure Period: 2018-11-01 to 2019-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3ACapitalExpenditure&period=2019-10-31&surface=latest&period_type=duration&start=2018-11-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 57379 USD (2018-11-01 to 2019-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495421000973/pbsv-20201031.xml#88051 Filing: 000165495421000973 The citation records this snapshot. The page link may show a newer release later.	−USD 2.27 million Calculation and evidence -2207739 − 57379 USD Exact free cash flow: -2265118 USD 2018-11-01 – 2019-10-31: -2207739 USD · Inspect Operating Cash Flow · Source 2018-11-01 – 2019-10-31: 57379 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pharma-Bio Serv, Inc. · 2019-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Free cash flow: -2265118 USD Concept: free-cash-flow Period: 2018-11-01 to 2019-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -2207739 USD (2018-11-01 to 2019-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495421000973/pbsv-20201031.xml#87296 Filing: 000165495421000973 Input fundies:CapitalExpenditure: 57379 USD (2018-11-01 to 2019-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495421000973/pbsv-20201031.xml#88051 Filing: 000165495421000973 The citation records this snapshot. The page link may show a newer release later.
2020 2019-11-01 – 2020-10-31	USD 2.05 million Exact value Exact value: 2050922 USD 2019-11-01 – 2020-10-31: 2050922 USD Inspect Net Income Open source Share or cite Citation for Net Income · Pharma-Bio Serv, Inc. · 2020-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Net Income: 2050922 USD Concept: fundies:NetIncome Period: 2019-11-01 to 2020-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3ANetIncome&period=2020-10-31&surface=latest&period_type=duration&start=2019-11-01&unit=USD&dimensions= Input fundies:NetIncome: 2050922 USD (2019-11-01 to 2020-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495422001532/pbsv_10k.htm#657309 Filing: 000165495422001532 The citation records this snapshot. The page link may show a newer release later.	USD 1.51 million Exact value Exact value: 1514412 USD 2019-11-01 – 2020-10-31: 1514412 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pharma-Bio Serv, Inc. · 2020-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Operating Cash Flow: 1514412 USD Concept: fundies:OperatingCashFlow Period: 2019-11-01 to 2020-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3AOperatingCashFlow&period=2020-10-31&surface=latest&period_type=duration&start=2019-11-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 1514412 USD (2019-11-01 to 2020-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495422001532/pbsv_10k.htm#671631 Filing: 000165495422001532 The citation records this snapshot. The page link may show a newer release later.	USD 55,657 Exact value Exact value: 55657 USD 2019-11-01 – 2020-10-31: 55657 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pharma-Bio Serv, Inc. · 2020-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Capital Expenditure: 55657 USD Concept: fundies:CapitalExpenditure Period: 2019-11-01 to 2020-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3ACapitalExpenditure&period=2020-10-31&surface=latest&period_type=duration&start=2019-11-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 55657 USD (2019-11-01 to 2020-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495422001532/pbsv_10k.htm#675386 Filing: 000165495422001532 The citation records this snapshot. The page link may show a newer release later.	USD 1.46 million Calculation and evidence 1514412 − 55657 USD Exact free cash flow: 1458755 USD 2019-11-01 – 2020-10-31: 1514412 USD · Inspect Operating Cash Flow · Source 2019-11-01 – 2020-10-31: 55657 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pharma-Bio Serv, Inc. · 2020-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Free cash flow: 1458755 USD Concept: free-cash-flow Period: 2019-11-01 to 2020-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 1514412 USD (2019-11-01 to 2020-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495422001532/pbsv_10k.htm#671631 Filing: 000165495422001532 Input fundies:CapitalExpenditure: 55657 USD (2019-11-01 to 2020-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495422001532/pbsv_10k.htm#675386 Filing: 000165495422001532 The citation records this snapshot. The page link may show a newer release later.
2021 2020-11-01 – 2021-10-31	−USD 2.09 million Exact value Exact value: -2089240 USD 2020-11-01 – 2021-10-31: -2089240 USD Inspect Net Income Open source Share or cite Citation for Net Income · Pharma-Bio Serv, Inc. · 2021-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Net Income: -2089240 USD Concept: fundies:NetIncome Period: 2020-11-01 to 2021-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3ANetIncome&period=2021-10-31&surface=latest&period_type=duration&start=2020-11-01&unit=USD&dimensions= Input fundies:NetIncome: -2089240 USD (2020-11-01 to 2021-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495423001018/pbsv_10k.htm#630211 Filing: 000165495423001018 The citation records this snapshot. The page link may show a newer release later.	USD 804,842 Exact value Exact value: 804842 USD 2020-11-01 – 2021-10-31: 804842 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pharma-Bio Serv, Inc. · 2021-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Operating Cash Flow: 804842 USD Concept: fundies:OperatingCashFlow Period: 2020-11-01 to 2021-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3AOperatingCashFlow&period=2021-10-31&surface=latest&period_type=duration&start=2020-11-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 804842 USD (2020-11-01 to 2021-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495423001018/pbsv_10k.htm#644686 Filing: 000165495423001018 The citation records this snapshot. The page link may show a newer release later.	USD 10,845 Exact value Exact value: 10845 USD 2020-11-01 – 2021-10-31: 10845 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pharma-Bio Serv, Inc. · 2021-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Capital Expenditure: 10845 USD Concept: fundies:CapitalExpenditure Period: 2020-11-01 to 2021-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3ACapitalExpenditure&period=2021-10-31&surface=latest&period_type=duration&start=2020-11-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 10845 USD (2020-11-01 to 2021-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495423001018/pbsv_10k.htm#648440 Filing: 000165495423001018 The citation records this snapshot. The page link may show a newer release later.	USD 793,997 Calculation and evidence 804842 − 10845 USD Exact free cash flow: 793997 USD 2020-11-01 – 2021-10-31: 804842 USD · Inspect Operating Cash Flow · Source 2020-11-01 – 2021-10-31: 10845 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pharma-Bio Serv, Inc. · 2021-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Free cash flow: 793997 USD Concept: free-cash-flow Period: 2020-11-01 to 2021-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 804842 USD (2020-11-01 to 2021-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495423001018/pbsv_10k.htm#644686 Filing: 000165495423001018 Input fundies:CapitalExpenditure: 10845 USD (2020-11-01 to 2021-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495423001018/pbsv_10k.htm#648440 Filing: 000165495423001018 The citation records this snapshot. The page link may show a newer release later.
2022 2021-11-01 – 2022-10-31	USD 1.01 million Exact value Exact value: 1006684 USD 2021-11-01 – 2022-10-31: 1006684 USD Inspect Net Income Open source Share or cite Citation for Net Income · Pharma-Bio Serv, Inc. · 2022-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Net Income: 1006684 USD Concept: fundies:NetIncome Period: 2021-11-01 to 2022-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3ANetIncome&period=2022-10-31&surface=latest&period_type=duration&start=2021-11-01&unit=USD&dimensions= Input fundies:NetIncome: 1006684 USD (2021-11-01 to 2022-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495424000996/pbsv_10k.htm#645085 Filing: 000165495424000996 The citation records this snapshot. The page link may show a newer release later.	USD 592,457 Exact value Exact value: 592457 USD 2021-11-01 – 2022-10-31: 592457 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pharma-Bio Serv, Inc. · 2022-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Operating Cash Flow: 592457 USD Concept: fundies:OperatingCashFlow Period: 2021-11-01 to 2022-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3AOperatingCashFlow&period=2022-10-31&surface=latest&period_type=duration&start=2021-11-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 592457 USD (2021-11-01 to 2022-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495424000996/pbsv_10k.htm#658170 Filing: 000165495424000996 The citation records this snapshot. The page link may show a newer release later.	USD 19,269 Exact value Exact value: 19269 USD 2021-11-01 – 2022-10-31: 19269 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pharma-Bio Serv, Inc. · 2022-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Capital Expenditure: 19269 USD Concept: fundies:CapitalExpenditure Period: 2021-11-01 to 2022-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3ACapitalExpenditure&period=2022-10-31&surface=latest&period_type=duration&start=2021-11-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 19269 USD (2021-11-01 to 2022-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495424000996/pbsv_10k.htm#661920 Filing: 000165495424000996 The citation records this snapshot. The page link may show a newer release later.	USD 573,188 Calculation and evidence 592457 − 19269 USD Exact free cash flow: 573188 USD 2021-11-01 – 2022-10-31: 592457 USD · Inspect Operating Cash Flow · Source 2021-11-01 – 2022-10-31: 19269 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pharma-Bio Serv, Inc. · 2022-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Free cash flow: 573188 USD Concept: free-cash-flow Period: 2021-11-01 to 2022-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 592457 USD (2021-11-01 to 2022-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495424000996/pbsv_10k.htm#658170 Filing: 000165495424000996 Input fundies:CapitalExpenditure: 19269 USD (2021-11-01 to 2022-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495424000996/pbsv_10k.htm#661920 Filing: 000165495424000996 The citation records this snapshot. The page link may show a newer release later.
2023 2022-11-01 – 2023-10-31	USD 1.31 million Exact value Exact value: 1310180 USD 2022-11-01 – 2023-10-31: 1310180 USD Inspect Net Income Open source Share or cite Citation for Net Income · Pharma-Bio Serv, Inc. · 2023-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Net Income: 1310180 USD Concept: fundies:NetIncome Period: 2022-11-01 to 2023-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3ANetIncome&period=2023-10-31&surface=latest&period_type=duration&start=2022-11-01&unit=USD&dimensions= Input fundies:NetIncome: 1310180 USD (2022-11-01 to 2023-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495425000915/pbsv_10k.htm#816501 Filing: 000165495425000915 The citation records this snapshot. The page link may show a newer release later.	USD 1.89 million Exact value Exact value: 1890960 USD 2022-11-01 – 2023-10-31: 1890960 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pharma-Bio Serv, Inc. · 2023-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Operating Cash Flow: 1890960 USD Concept: fundies:OperatingCashFlow Period: 2022-11-01 to 2023-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3AOperatingCashFlow&period=2023-10-31&surface=latest&period_type=duration&start=2022-11-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 1890960 USD (2022-11-01 to 2023-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495425000915/pbsv_10k.htm#690703 Filing: 000165495425000915 The citation records this snapshot. The page link may show a newer release later.	USD 7,251 Exact value Exact value: 7251 USD 2022-11-01 – 2023-10-31: 7251 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pharma-Bio Serv, Inc. · 2023-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Capital Expenditure: 7251 USD Concept: fundies:CapitalExpenditure Period: 2022-11-01 to 2023-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3ACapitalExpenditure&period=2023-10-31&surface=latest&period_type=duration&start=2022-11-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7251 USD (2022-11-01 to 2023-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495425000915/pbsv_10k.htm#694467 Filing: 000165495425000915 The citation records this snapshot. The page link may show a newer release later.	USD 1.88 million Calculation and evidence 1890960 − 7251 USD Exact free cash flow: 1883709 USD 2022-11-01 – 2023-10-31: 1890960 USD · Inspect Operating Cash Flow · Source 2022-11-01 – 2023-10-31: 7251 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pharma-Bio Serv, Inc. · 2023-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Free cash flow: 1883709 USD Concept: free-cash-flow Period: 2022-11-01 to 2023-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 1890960 USD (2022-11-01 to 2023-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495425000915/pbsv_10k.htm#690703 Filing: 000165495425000915 Input fundies:CapitalExpenditure: 7251 USD (2022-11-01 to 2023-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495425000915/pbsv_10k.htm#694467 Filing: 000165495425000915 The citation records this snapshot. The page link may show a newer release later.
2024 2023-11-01 – 2024-10-31	−USD 777,619 Exact value Exact value: -777619 USD 2023-11-01 – 2024-10-31: -777619 USD Inspect Net Income Open source Share or cite Citation for Net Income · Pharma-Bio Serv, Inc. · 2024-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Net Income: -777619 USD Concept: fundies:NetIncome Period: 2023-11-01 to 2024-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3ANetIncome&period=2024-10-31&surface=latest&period_type=duration&start=2023-11-01&unit=USD&dimensions= Input fundies:NetIncome: -777619 USD (2023-11-01 to 2024-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495426000710/pbsv_10k.htm#838503 Filing: 000165495426000710 The citation records this snapshot. The page link may show a newer release later.	−USD 566,701 Exact value Exact value: -566701 USD 2023-11-01 – 2024-10-31: -566701 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pharma-Bio Serv, Inc. · 2024-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Operating Cash Flow: -566701 USD Concept: fundies:OperatingCashFlow Period: 2023-11-01 to 2024-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3AOperatingCashFlow&period=2024-10-31&surface=latest&period_type=duration&start=2023-11-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -566701 USD (2023-11-01 to 2024-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495426000710/pbsv_10k.htm#723804 Filing: 000165495426000710 The citation records this snapshot. The page link may show a newer release later.	USD 159,743 Exact value Exact value: 159743 USD 2023-11-01 – 2024-10-31: 159743 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pharma-Bio Serv, Inc. · 2024-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Capital Expenditure: 159743 USD Concept: fundies:CapitalExpenditure Period: 2023-11-01 to 2024-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3ACapitalExpenditure&period=2024-10-31&surface=latest&period_type=duration&start=2023-11-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 159743 USD (2023-11-01 to 2024-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495426000710/pbsv_10k.htm#727527 Filing: 000165495426000710 The citation records this snapshot. The page link may show a newer release later.	−USD 726,444 Calculation and evidence -566701 − 159743 USD Exact free cash flow: -726444 USD 2023-11-01 – 2024-10-31: -566701 USD · Inspect Operating Cash Flow · Source 2023-11-01 – 2024-10-31: 159743 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pharma-Bio Serv, Inc. · 2024-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Free cash flow: -726444 USD Concept: free-cash-flow Period: 2023-11-01 to 2024-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -566701 USD (2023-11-01 to 2024-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495426000710/pbsv_10k.htm#723804 Filing: 000165495426000710 Input fundies:CapitalExpenditure: 159743 USD (2023-11-01 to 2024-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495426000710/pbsv_10k.htm#727527 Filing: 000165495426000710 The citation records this snapshot. The page link may show a newer release later.
2025 2024-11-01 – 2025-10-31	−USD 100,463 Exact value Exact value: -100463 USD 2024-11-01 – 2025-10-31: -100463 USD Inspect Net Income Open source Share or cite Citation for Net Income · Pharma-Bio Serv, Inc. · 2025-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Net Income: -100463 USD Concept: fundies:NetIncome Period: 2024-11-01 to 2025-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3ANetIncome&period=2025-10-31&surface=latest&period_type=duration&start=2024-11-01&unit=USD&dimensions= Input fundies:NetIncome: -100463 USD (2024-11-01 to 2025-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495426000710/pbsv_10k.htm#837901 Filing: 000165495426000710 The citation records this snapshot. The page link may show a newer release later.	−USD 214,886 Exact value Exact value: -214886 USD 2024-11-01 – 2025-10-31: -214886 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pharma-Bio Serv, Inc. · 2025-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Operating Cash Flow: -214886 USD Concept: fundies:OperatingCashFlow Period: 2024-11-01 to 2025-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3AOperatingCashFlow&period=2025-10-31&surface=latest&period_type=duration&start=2024-11-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -214886 USD (2024-11-01 to 2025-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495426000710/pbsv_10k.htm#723122 Filing: 000165495426000710 The citation records this snapshot. The page link may show a newer release later.	USD 6,644 Exact value Exact value: 6644 USD 2024-11-01 – 2025-10-31: 6644 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pharma-Bio Serv, Inc. · 2025-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Capital Expenditure: 6644 USD Concept: fundies:CapitalExpenditure Period: 2024-11-01 to 2025-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161/explain?concept=fundies%3ACapitalExpenditure&period=2025-10-31&surface=latest&period_type=duration&start=2024-11-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6644 USD (2024-11-01 to 2025-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495426000710/pbsv_10k.htm#726926 Filing: 000165495426000710 The citation records this snapshot. The page link may show a newer release later.	−USD 221,530 Calculation and evidence -214886 − 6644 USD Exact free cash flow: -221530 USD 2024-11-01 – 2025-10-31: -214886 USD · Inspect Operating Cash Flow · Source 2024-11-01 – 2025-10-31: 6644 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pharma-Bio Serv, Inc. · 2025-10-31 Pharma-Bio Serv, Inc. (edgar:1304161) Free cash flow: -221530 USD Concept: free-cash-flow Period: 2024-11-01 to 2025-10-31 Values: Latest reported Published: 2026-11-02T14:11:46Z Snapshot: 48f112a23ef56a6032e00e25fdbc1049508386de4821108aed8e036a724a517f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1304161?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -214886 USD (2024-11-01 to 2025-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495426000710/pbsv_10k.htm#723122 Filing: 000165495426000710 Input fundies:CapitalExpenditure: 6644 USD (2024-11-01 to 2025-10-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1304161/000165495426000710/pbsv_10k.htm#726926 Filing: 000165495426000710 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

119 filings · 4,686 latest values · 4,686 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001304161, 1304161, PBSV, edgar:1304161

Also known as LAWRENCE CONSULTING GROUP INC, PHARMA-BIO SERV, INC., Pharma-Bio Serv, Inc.

Pharma-Bio Serv, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2024-11-01 – 2025-10-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation